Prescient Therapeutics Management
Management criteria checks 3/4
Prescient Therapeutics' CEO is Steven Yatomi-Clarke, appointed in Feb 2016, has a tenure of 8.42 years. total yearly compensation is A$663.24K, comprised of 60.3% salary and 39.7% bonuses, including company stock and options. directly owns 1.39% of the company’s shares, worth A$503.77K. The average tenure of the management team and the board of directors is 8.4 years and 9.2 years respectively.
Key information
Steven Yatomi-Clarke
Chief executive officer
AU$663.2k
Total compensation
| CEO salary percentage | 60.3% |
| CEO tenure | 8.4yrs |
| CEO ownership | 1.4% |
| Management average tenure | 8.4yrs |
| Board average tenure | 9.2yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$8m |
| Sep 30 2023 | n/a | n/a | -AU$7m |
| Jun 30 2023 | AU$663k | AU$400k | -AU$7m |
| Mar 31 2023 | n/a | n/a | -AU$6m |
| Dec 31 2022 | n/a | n/a | -AU$5m |
| Sep 30 2022 | n/a | n/a | -AU$5m |
| Jun 30 2022 | AU$771k | AU$392k | -AU$5m |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$5m |
| Sep 30 2021 | n/a | n/a | -AU$5m |
| Jun 30 2021 | AU$800k | AU$360k | -AU$4m |
| Mar 31 2021 | n/a | n/a | -AU$4m |
| Dec 31 2020 | n/a | n/a | -AU$3m |
| Sep 30 2020 | n/a | n/a | -AU$3m |
| Jun 30 2020 | AU$639k | AU$392k | -AU$3m |
| Mar 31 2020 | n/a | n/a | -AU$4m |
| Dec 31 2019 | n/a | n/a | -AU$4m |
| Sep 30 2019 | n/a | n/a | -AU$4m |
| Jun 30 2019 | AU$586k | AU$367k | -AU$4m |
| Mar 31 2019 | n/a | n/a | -AU$3m |
| Dec 31 2018 | n/a | n/a | -AU$3m |
| Sep 30 2018 | n/a | n/a | -AU$3m |
| Jun 30 2018 | AU$479k | AU$330k | -AU$3m |
Compensation vs Market: Steven's total compensation ($USD434.60K) is above average for companies of similar size in the Australian market ($USD292.71K).
Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.
CEO
Steven Yatomi-Clarke
8.4yrs
Tenure
AU$663,236
Compensation
Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 8.4yrs | AU$663.24k | 1.39% A$ 503.8k | |
| Director of Clinical Affairs & Operations | less than a year | no data | no data | |
| Chief Medical Officer | 9.3yrs | AU$157.36k | no data | |
| Senior Vice President of Scientific Affairs | 2.5yrs | no data | no data | |
| Company Secretary | 9.4yrs | AU$158.40k | no data |
8.4yrs
Average Tenure
Experienced Management: PTX's management team is seasoned and experienced (8.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 9.7yrs | AU$663.24k | 1.39% A$ 503.8k | |
| Independent Non-Executive Chairman | 10.1yrs | AU$106.05k | 0.027% A$ 9.9k | |
| Independent Non-Executive Director | 9.7yrs | AU$65.26k | 0.049% A$ 17.8k | |
| Chairman of Clinical Advisory Board | 13.1yrs | no data | no data | |
| Member of Clinical Advisory Board | 13.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.5yrs | no data | no data | |
| Non-Executive Director | 4.1yrs | AU$65.26k | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data |
9.2yrs
Average Tenure
Experienced Board: PTX's board of directors are considered experienced (9.2 years average tenure).